{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:18:17Z","timestamp":1788787097836,"version":"build-2803163510"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recovery of endogenous testosterone following androgen deprivation therapy (ADT) for prostate cancer is uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To prospectively evaluate testosterone (T) recovery rates and timing after neoadjuvant ADT followed by radical prostatectomy (RP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report a secondary analysis from a phase II randomized trial involving 64 patients who received a 3-month neoadjuvant ADT regimen (goserelin, abiraterone with prednisone and for half of the participants, apalutamide) followed by RP. Total Testosterone (TT) was measured at baseline, during ADT (3\u00a0m), and after 4, 8, and 12\u00a0months post-ADT cessation. Return to non-castrate levels (TT\u2009&amp;gt;\u200950\u00a0ng\/dL), to normal (TT\u2009\u2265\u2009300\u00a0ng\/dL), and back to baseline level (BTB, defined as TT\u2009\u2265\u2009baseline) are reported. Predictive factors were analyzed using uni and multivariate analyses (MVA), and quality of life (QoL) was assessed with the validated Expanded Prostate Cancer Index Composite (EPIC-50).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Chance and chronology of T recovery 1\u00a0year after ADT cessation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median T levels were as follows: baseline 442\u00a0ng\/dL (IQR: 321\u2013505); 4\u00a0months post-ADT, 144\u00a0ng\/dL (IQR: 35\u2013284); 8\u00a0months, 316\u00a0ng\/dL (IQR: 243\u2013438); and 12\u00a0months, 358\u00a0ng\/dL (IQR: 285\u2013477). By 12\u00a0months, 98.1% of patients reached non-castrate levels, 79.5% returned to normal, and 33.9% to BTB. Half of the patients achieved T\u2009&amp;gt;\u200950\u00a0ng\/dL in 5\u00a0months, T\u2009\u2265\u2009300\u00a0ng\/dL in 9.1\u00a0months, and BTB in 13.1\u00a0months. In MVA, baseline T was the only significant predictor for T normalization (OR: 1.015; P\u00a0&amp;lt;\u2009.01), while age and baseline T were predictors for BTB recovery (OR for age: 0.88; P\u00a0=\u2009.02; OR for baseline T: 0.99; P\u00a0=\u2009.02). QoL assessment showed persistently low sexual function, with minor improvements over time (median scores: 0 [0\u20135.6] at 4\u00a0months and 2.8 [0\u201329.2] at 12\u00a0months, P\u00a0&amp;lt;\u2009.01), while sexual bother starts very low but significantly increases during follow up (median scores: 100 [IQR: 42.2\u2013100] at 4\u00a0months to 50 [IQR: 0\u2013100] at 12\u00a0months, P\u00a0=\u2009.03).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Long-term lower T levels can occur even after short-term ADT, persisting longer than anticipated. Clinicians should consider this in patient management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>Our strengths include the prospective, controlled design and a rarely reported ADT triple therapy followed by RP. Limitations include the use of immunoassay to measure TT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>After 3\u00a0months of neoadjuvant triple ADT and RP, significant recovery to non-castrate and normal T levels is seen in most patients by 1\u00a0year; yet, BTB recovery is achieved in only a third. Higher baseline T and younger age predict faster T normalization and BTB recovery, respectively.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf164","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:46:37Z","timestamp":1753191997000},"page":"1554-1563","source":"Crossref","is-referenced-by-count":2,"title":["Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-4434","authenticated-orcid":false,"given":"Bruno Chiesa G","family":"Nascimento","sequence":"first","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubens","family":"Pedrenho","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C E","family":"Zandon\u00e1","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas V","family":"Sanvido","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4833-4889","authenticated-orcid":false,"given":"Jos\u00e9","family":"Bessa Junior","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Universidade Estadual de Feira de Santana , Avenida Transnordestina, s\/n, Novo Horizonte, Feira de Santana - Bahia - CEP 44036-900 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3552-5400","authenticated-orcid":false,"given":"Eduardo de P","family":"Miranda","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo A","family":"Bastos","sequence":"additional","affiliation":[{"name":"Centro de Oncologia, Hospital S\u00edrio-Liban\u00eas , Rua Dona Adma Jafet, 115, Bela Vista, S\u00e3o Paulo - SP, CEP 01308-050 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio D","family":"Cordeiro","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Coelho","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Nahas","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hallak","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Mulhall","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program , Urology Service, Memorial SloanKettering Cancer Center, 205 E 64th St, New York, NY 10022, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano M","family":"Gomes","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Urologia, Hospital das Cl\u00ednicas\u2014Faculdade de Medicina da Universidade de S\u00e3o Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 255, Cerqueira C\u00e9sar, S\u00e3o Paulo - SP - CEP 05403-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2025090408015701800_ref1","doi-asserted-by":"publisher","volume-title":"CA Cancer J Clin","DOI":"10.3322\/caac.21820"},{"issue":"4","key":"2025090408015701800_ref2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"2025090408015701800_ref3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaccao.2021.09.014","article-title":"How to treat prostate cancer with androgen deprivation and minimize cardiovascular risk: a therapeutic tightrope","volume":"3","author":"Narayan","year":"2021","journal-title":"JACC CardioOncology"},{"issue":"2","key":"2025090408015701800_ref4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and Management of Testosterone Deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"5","key":"2025090408015701800_ref5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"2025090408015701800_ref6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bju.14899","article-title":"Guideline of guidelines: testosterone therapy for testosterone deficiency","volume":"124","author":"Salter","year":"2019","journal-title":"BJU Int"},{"issue":"3","key":"2025090408015701800_ref7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.eururo.2021.06.007","article-title":"European Association of Urology Guidelines on Sexual and Reproductive Health\u20142021 update: male sexual dysfunction","volume":"80","author":"Salonia","year":"2021","journal-title":"Eur Urol"},{"issue":"6","key":"2025090408015701800_ref8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jsxm.2019.03.273","article-title":"Testosterone recovery profiles after cessation of androgen deprivation therapy for prostate cancer","volume":"16","author":"Nascimento","year":"2019","journal-title":"J Sex Med"},{"issue":"6","key":"2025090408015701800_ref9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/21681805.2016.1227876","article-title":"Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer","volume":"50","author":"Planas","year":"2016","journal-title":"Scand J Urol"},{"issue":"2","key":"2025090408015701800_ref10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cncr.10219","article-title":"Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma","volume":"94","author":"Pickles","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"2025090408015701800_ref11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5489\/cuaj.10102","article-title":"Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists","volume":"5","author":"Pai","year":"2011","journal-title":"Can Urol Assoc J J Assoc Urol Can"},{"issue":"5","key":"2025090408015701800_ref12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0022-5347(01)62383-8","article-title":"Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration","volume":"160","author":"Oefelein","year":"1998","journal-title":"J Urol"},{"issue":"1","key":"2025090408015701800_ref13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4111\/icu.2018.59.1.18","article-title":"Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer","volume":"59","author":"Nam","year":"2018","journal-title":"Investig Clin Urol"},{"issue":"4","key":"2025090408015701800_ref14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/aja.2012.169","article-title":"Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy","volume":"15","author":"Dai","year":"2013","journal-title":"Asian J Androl"},{"issue":"1","key":"2025090408015701800_ref15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5534\/wjmh.210178","article-title":"Testosterone recovery after androgen deprivation therapy in prostate cancer: building a predictive model","volume":"41","author":"Borque-Fernando","year":"2023","journal-title":"World J Mens Health"},{"issue":"5","key":"2025090408015701800_ref16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2025090408015701800_ref17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2025090408015701800_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.02.1363","article-title":"PD27-12 development of nomograms to predict testoterone recovery after cessation of androgen deprivation therapy in men with prostate cancer","volume":"199","author":"Bernie","year":"2018","journal-title":"J Urol"},{"issue":"6","key":"2025090408015701800_ref19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/s0090-4295(00)00858-x","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"issue":"6","key":"2025090408015701800_ref20","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.eururo.2007.05.021","article-title":"Relationship between the Saint Louis University ADAM questionnaire and sexual hormonal levels in a male outpatient population over 50 years of age","volume":"52","author":"Mart\u00ednez-Jabaloyas","year":"2007","journal-title":"Eur Urol"},{"issue":"1","key":"2025090408015701800_ref21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/ijir.2009.35","article-title":"The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism","volume":"22","author":"Mohamed","year":"2010","journal-title":"Int J Impot Res"},{"issue":"3","key":"2025090408015701800_ref22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1590\/S1677-5538.IBJU.2013.03.07","article-title":"Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy","volume":"39","author":"Alves","year":"2013","journal-title":"Int Braz J Urol Off J Braz Soc Urol"},{"issue":"10336","key":"2025090408015701800_ref23","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"21","key":"2025090408015701800_ref24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2025090408015701800_ref25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025090408015701800_ref26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/aja.2011.103","article-title":"Use of androgen deprivation therapy in prostate cancer: indications and prevalence","volume":"14","author":"Connolly","year":"2012","journal-title":"Asian J Androl"},{"issue":"4","key":"2025090408015701800_ref27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/pros.20341","article-title":"Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer","volume":"66","author":"Kaku","year":"2006","journal-title":"Prostate"},{"issue":"1","key":"2025090408015701800_ref28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","article-title":"Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): a pooled analysis of five randomized trials from the meta-analysis of randomized trials in cancer of the prostate (MARCAP)","volume":"87","author":"Ong","year":"2024","journal-title":"Consortium Eur Urol"},{"issue":"1","key":"2025090408015701800_ref29","doi-asserted-by":"publisher","first-page":"65.e1","DOI":"10.1016\/j.urolonc.2024.08.005","article-title":"Testosterone recovery after androgen deprivation therapy","volume":"43","author":"Ho","year":"2024","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"6","key":"2025090408015701800_ref30","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/j.1464-410X.2007.06843.x","article-title":"Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer","volume":"99","author":"Murthy","year":"2007","journal-title":"BJU Int"},{"issue":"4","key":"2025090408015701800_ref31","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.euo.2023.11.024","article-title":"Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: results from the phase 3 HERO study","volume":"7","author":"Tutrone","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"23","key":"2025090408015701800_ref32","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"2025090408015701800_ref33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"issue":"10","key":"2025090408015701800_ref34","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"2025090408015701800_ref35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41443-019-0116-0","article-title":"Pre- and post-radical prostatectomy testosterone levels in prostate cancer patients","volume":"31","author":"Lumbiganon","year":"2019","journal-title":"Int J Impot Res"},{"issue":"3","key":"2025090408015701800_ref36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.adro.2021.100851","article-title":"The long-term effect of intensity modulated radiation therapy for prostate cancer on testosterone levels","volume":"7","author":"Horiguchi","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"2025090408015701800_ref37","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/j.prro.2014.10.003","article-title":"The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer","volume":"5","author":"Son","year":"2015","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"2025090408015701800_ref38","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.urology.2013.06.062","article-title":"Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality\/hormonal and sexual quality of life: results of a multicenter prospective study","volume":"82","author":"Gay","year":"2013","journal-title":"Urology"},{"key":"2025090408015701800_ref39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/RRU.S342063","article-title":"Impacts of neoadjuvant hormonal therapy prior to robot-assisted radical prostatectomy on postoperative hormonal- and sexual-related quality of life\u2014assessment by patient-reported questionnaire","volume":"Volume 14","author":"Ogawa","year":"2022","journal-title":"Res Rep Urol"},{"issue":"9","key":"2025090408015701800_ref40","doi-asserted-by":"publisher","first-page":"e0239469","DOI":"10.1371\/journal.pone.0239469","article-title":"Quality of life and adjustment in men with prostate cancer: interplay of stress, threat and resilience","volume":"15","author":"Groarke","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"2025090408015701800_ref41","doi-asserted-by":"publisher","first-page":"pkaa044","DOI":"10.1093\/jncics\/pkaa044","article-title":"The relative impact of urinary and sexual function vs bother on health utility for men with prostate cancer","volume":"4","author":"Jeong","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"2025090408015701800_ref42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/pon.4463","article-title":"Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: a controlled comparison","volume":"27","author":"Donovan","year":"2018","journal-title":"Psychooncology"},{"issue":"2","key":"2025090408015701800_ref43","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.ijrobp.2011.06.010","article-title":"A phase III randomized trial of intermittent vs. continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7\/SWOG JPR.7\/CTSU JPR.7\/ UK intercontinental trial CRUKE\/01\/013)","volume":"81","author":"Crook","year":"2011","journal-title":"Int J Radiat Oncol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/9\/1554\/63818307\/qdaf164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/9\/1554\/63818307\/qdaf164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:02:05Z","timestamp":1756987325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/9\/1554\/8210339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf164","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,22]]}}}